Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Total Liabilities of $175.2 million for Q1 2026, up 7.36% year-over-year from $163.2 million in Q1 2025, and down 9.74% quarter-over-quarter from $194.1 million in Q4 2025.
Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Total Liabilities history runs 10 years deep, the most recent figure standing at $175.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 7.36% year-over-year to $175.2 million; the TTM figure through Mar 2026 stood at $175.2 million (up 7.36% YoY), while the FY2025 annual figure was $194.1 million, up 20.12% from the prior year.
- Total Liabilities for Q1 2026 stood at $175.2 million, down from $194.1 million in the prior quarter.
- The five-year high for Total Liabilities was $194.1 million in Q4 2025, with the low at $149.7 million in Q1 2022.
- The 5-year median for Total Liabilities is $163.6 million (2023), against an average of $164.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities soared 31.61% in 2022, then retreated 6.67% in 2023.
- Aquestive Therapeutics' Total Liabilities stood at $175.6 million in 2022, then retreated by 6.67% to $163.9 million in 2023, then decreased by 1.42% to $161.6 million in 2024, then rose by 20.12% to $194.1 million in 2025, then fell by 9.74% to $175.2 million in 2026.
- Business Quant data shows AQST's Total Liabilities at $175.2 million in Q1 2026, $194.1 million in Q4 2025, and $167.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.12 Bn |
| 10 | Aquestive Therapeutics | 554.85 Mn | 554.85 Mn | 9.80 Mn | 188.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188.69 Mn |
| Mar 31, 2026 | 175.18 Mn |
| Dec 31, 2025 | 194.09 Mn |
| Sep 30, 2025 | 167.67 Mn |
| Jun 30, 2025 | 166.29 Mn |
| Mar 31, 2025 | 163.16 Mn |
| Dec 31, 2024 | 161.58 Mn |
| Sep 30, 2024 | 155.38 Mn |
| Jun 30, 2024 | 153.08 Mn |
| Mar 31, 2024 | 165.82 Mn |
| Dec 31, 2023 | 163.91 Mn |
| Sep 30, 2023 | 162.38 Mn |
| Jun 30, 2023 | 163.65 Mn |
| Mar 31, 2023 | 170.52 Mn |
| Dec 31, 2022 | 175.62 Mn |
| Sep 30, 2022 | 159.66 Mn |
| Jun 30, 2022 | 152.67 Mn |
| Mar 31, 2022 | 149.67 Mn |
| Dec 31, 2021 | 144.13 Mn |
| Sep 30, 2021 | 125.64 Mn |